| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 45.9 | 43.7 | 38.8 |
| Other income | 0.1 | 0.1 | 0.1 |
| Total income | 46.0 | 43.8 | 38.9 |
| Profit before exceptional items & tax | 6.7 | 6.4 | 6.5 |
| Profit before tax | 6.7 | 6.4 | 6.5 |
| Net profit | 4.9 | 4.8 | 4.3 |
| Operating margin | 14.6% | 14.6% | 16.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.00% |
|---|---|
| Net profit, quarter on quarter | +2.10% |
| Revenue, year on year | +18.30% |
Source
Read the filing ↗
NSE results filing, NSE: ACCPL. Figures extracted from the filing.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹203.30
- Market cap
- ₹226.0 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 23.4×Sector 50.4×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →
20:31 IST
NSE
Annual General Meeting
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
14:48 IST
NSE
Earnings Call
Accretion Pharmaceuticals Earnings Call: Key Takeaways
Accretion Pharmaceuticals reported strong FY26 performance with ₹89.63 cr total income and 10.8% PAT margin, driven by export growth.